This is a preview of subscription content, log in via an institution to check access.
Notes
values reflect 2005 international dollars in all three studies; in the analyses in sub-Saharan Africa and EMENA, the cost per vaccinated girl included vaccine dosages, wastage, administration, freight, supplies, administration, support and other programme-related costs
References
Kim JJ, et al. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-saharan Africa. Vaccine 31 (Suppl. 5): F60-72, 29 Dec 2013. Available from: URL: http://dx.doi.org/10.1016/j.vaccine.2012.07.093
Kim JJ, et al. Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in the Extended Middle East and North Africa (EMENA). Vaccine 31 (Suppl. 6): G65-77, 30 Dec 2013. Available from: URL: http://dx.doi.org/10.1016/j.vaccine.2012.06.096
Berkhof J, et al. Cost-effectiveness of cervical cancer prevention in central and eastern europe and central Asia. Vaccine 31 (Suppl. 7): H71-9, 31 Dec 2013. Available from: URL: http://dx.doi.org/10.1016/j.vaccine.2013.04.086
Rights and permissions
About this article
Cite this article
Cervical cancer prevention cost effective in developing countries. PharmacoEcon Outcomes News 695, 3 (2014). https://doi.org/10.1007/s40274-014-0994-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-0994-9